Back to top
more

Cellectar Biosciences (CLRB)

(Delayed Data from NSDQ)

$2.03 USD

2.03
138,599

-0.01 (-0.49%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $2.02 -0.01 (-0.49%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Cellectar Biosciences to Present at IWWM Featuring Iopofosine I 131

by Zacks Equity Research

CLRB announces two presentations featuring its Iopofosine I 131 at the 12th IWWM, in Prague. Jorge Castillo will be the presenter.

What's in Store for Cooper Companies (COO) in Q3 Earnings?

by Zacks Equity Research

Cooper Companies' (COO) fiscal third-quarter results are likely to reflect segmental strength.

Broad Portfolio to Aid Patterson Companies' (PDCO) Q1 Earnings

by Zacks Equity Research

Patterson Companies' (PDCO) fiscal first-quarter results are likely to reflect an improvement in both the Dental and Animal Health segments on the back of comprehensive product offerings.

Reasons to Retain Cardinal Health (CAH) in Your Portfolio Now

by Zacks Equity Research

Cardinal Health (CAH) gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.

Here's Why You Should Retain Accuray (ARAY) Stock for Now

by Zacks Equity Research

Accuray's (ARAY) solid product demand raises optimism about the stock.

Is Cellectar Biosciences (CLRB) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Cellectar Biosciences, Inc. (CLRB) and InMode (INMD) have performed compared to their sector so far this year.

Is CanFite Biopharma Ltd (CANF) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how CanFite Biopharma Ltd (CANF) and Cellectar Biosciences, Inc. (CLRB) have performed compared to their sector so far this year.

Zacks.com featured highlights include: RentACenter, U.S. Physical Therapy, Cellectar Biosciences, Toro and Zymeworks

by Zacks Equity Research

RentACenter, U.S. Physical Therapy, Cellectar Biosciences, Toro and Zymeworks are highlighted in this Screen of the Week article.

Sanghamitra Saha headshot

Ride on Rising P/E Investing With These 5 Top-Ranked Stocks

by Sanghamitra Saha

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Baxter (BAX) Inks Sterile Manufacturing Agreement With Novavax

by Zacks Equity Research

Baxter's (BAX) BioPharma Solutions business inks deal to advance commercial-scale production and increase access for the COVID-19 vaccine in the U.K. and European markets.

Tirthankar Chakraborty headshot

5 Stocks to Invest in as Dollar Gets Its Mojo Back

by Tirthankar Chakraborty

The dollar has not only strengthened in recent times but it seems there is even more room for growth. So, let's find out which stocks stand to benefit from dollar's comeback.

Sanghamitra Saha headshot

Play Rising P/E Investing With These Top 5 Stocks

by Sanghamitra Saha

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

Biocept (BIOC) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Biocept (BIOC) is expected to have suffered in Q2 from reduced oncology practices and postponement of patient appointments.

Sanghamitra Saha headshot

What Bargain Hunting? Tap 5 Stocks With Rising P/E

by Sanghamitra Saha

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

Company News for May 27, 2020

by Zacks Equity Research

Companies In The News Are: EVFM, BNFT, SRNE, CLRB